UroGen Pharma Ltd. (URGN)
NASDAQ: URGN · Real-Time Price · USD
21.35
+0.83 (4.04%)
Feb 6, 2026, 4:00 PM EST - Market closed
UroGen Pharma Employees
UroGen Pharma had 287 employees as of September 30, 2025. The number of employees increased by 70 or 32.26% compared to the same quarter last year.
Employees
287
Change
70
Growth
32.26%
Revenue / Employee
$336,293
Profits / Employee
-$573,666
Market Cap
999.37M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Sep 30, 2025 | 287 | 70 | 32.26% | 287 | 0 |
| Jun 30, 2025 | 253 | 50 | 24.63% | 253 | 0 |
| Mar 31, 2025 | 234 | 30 | 14.71% | 234 | 0 |
| Dec 31, 2024 | 235 | 34 | 16.92% | 235 | 0 |
| Sep 30, 2024 | 217 | 25 | 13.02% | 217 | 0 |
| Jun 30, 2024 | 203 | 10 | 5.18% | 203 | 0 |
| Mar 31, 2024 | 204 | 10 | 5.15% | 204 | 0 |
| Dec 31, 2023 | 201 | 1 | 0.50% | 198 | 3 |
| Sep 30, 2023 | 192 | -3 | -1.54% | 192 | 0 |
| Jun 30, 2023 | 193 | -8 | -3.98% | 193 | 0 |
| Mar 31, 2023 | 194 | 2 | 1.04% | 194 | 0 |
| Dec 31, 2022 | 200 | 5 | 2.56% | 200 | 0 |
| Sep 30, 2022 | 195 | -3 | -1.52% | 195 | 0 |
| Jun 30, 2022 | 201 | 11 | 5.79% | 201 | 0 |
| Mar 31, 2022 | 192 | 2 | 1.05% | 192 | 0 |
| Dec 31, 2021 | 195 | 8 | 4.28% | 195 | 0 |
| Sep 30, 2021 | 198 | 11 | 5.88% | 198 | 0 |
| Jun 30, 2021 | 190 | 4 | 2.15% | 190 | 0 |
| Mar 31, 2021 | 190 | 16 | 9.20% | 190 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Iovance Biotherapeutics | 838 |
| AbCellera Biologics | 596 |
| Geron | 229 |
| ARS Pharmaceuticals | 167 |
| EyePoint | 165 |
| CytomX Therapeutics | 121 |
| Theravance Biopharma | 97 |
| Ventyx Biosciences | 83 |
URGN News
- 2 days ago - UroGen Pharma to Present at the Guggenheim Securities Emerging Outlook: Biotech Summit - GlobeNewsWire
- 4 weeks ago - Permanent J Code for ZUSDURI™ Now in Effect, Expanding Patient Access to Innovative Bladder Cancer Therapy - GlobeNewsWire
- 2 months ago - UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 2 months ago - UroGen Pharma: Strong Potential As Zusduri Commercialization Accelerates - Seeking Alpha
- 2 months ago - UroGen Pharma to Present at the Piper Sandler 37th Annual Healthcare Conference - GlobeNewsWire
- 3 months ago - UroGen Pharma Ltd. (URGN) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 3 months ago - UroGen Reports Third Quarter 2025 Financial Results as ZUSDURI™ Launch Gains Momentum - GlobeNewsWire
- 3 months ago - UroGen Reports 77.8% Three-Month Complete Response Rate from Phase 3 UTOPIA Trial of UGN-103 and Receives FDA Agreement on NDA Submission Strategy in Recurrent LG-IR-NMIBC Based on UTOPIA Trial - GlobeNewsWire